Using Dabigatran in Patients With Stroke

Abstract

Atrial fibrillation (AF) is 1 of the most common causes of cardioembolic strokes accounting for at least 100 000 strokes each year in the United States. Strokes due to AF tend to be larger and more severe than other types of ischemic strokes with a 30-day mortality rate up to 24%.1 Anticoagulation with warfarin can reduce the risk of stroke in patients with moderate- and high-risk AF by ≥65%,2 yet the use of warfarin is limited by a number of factors, including concerns about bleeding, the need for frequent international normalized ratio (INR) monitoring as well as significant and common food and drug interactions.3–6

Read More

Citation
Stroke 2012;43:271-9